Escherichia coli is part of the commensal microbiota of human’s and animal’s gut. However, they may become pathogenic due to the acquisition of virulence factors that provide the ability to cause intestinal or extraintestinal infections, which makes E. coli the main cause of diarrheagenic diseases and urinary tract infections (UTIs) worldwide, respectively. Some strains, known as hybrids, may harbour a mix of virulence determinants of both diarrheagenic (DEC) and extraintestinal E. coli (ExPEC) pathotypes. Reports of hybrid E. coli in Brazil are rare, and the lineages associated with such pathotypes were poorly explored. This study aimed to characterize E. coli strains recovered from extraintestinal infections in a clinical setting of the Brazilian Amazon Region by means of lineage determination, antibiotic resistance profile, and investigation of DEC and ExPEC virulence markers. Fifteen ExPEC strains were recovered from distinct extraintestinal sites from inpatients of the General Hospital of Roraima (GHR), placed in the Brazilian Amazon region. Antibiotic susceptibility test revealed that all strains were multidrug-resistant and most of them, including those recovered from urine, were resistant to fluoroquinolones, the main therapeutic option for treating UTIs, probably due to the presence of Ser83Leu and Asp87Asn substitutions in GyrA. The MLST analysis revealed the polyclonal nature of these ExPEC strains since 11 STs were determined, including local and pandemic lineages, such as ST69 and ST131. Among the 15 isolates, 12 were classified as hybrids, due to the presence of the aggR virulence marker of the Enteroaggregative E. coli (EAEC) pathotype together with at least one ExPEC (iutA, KPSMTII, sfaDE, papC, afaBC, iucD) or Uropathogenic E. coli (UPEC) (vat, fuyA, chuA and yfcV) virulence determinants. These UPEC/EAEC (n=10) and ExPEC/EAEC (n=2) hybrid strains were found among distinct lineages, including new STs, and phylogroups (ST131/B2; ST1196/AxB1; ST9403/A; ST12394/A; NEW1-CC14/B2; NEW2-CC155/B1; NEW3-CC155/B1; NEW4-CC131/B2) and, for the first time, a hybrid phenotype was found in the pandemic ST131 lineage in Brazil. Therefore, this study provides new information on the epidemiological scenario of hybrid E. coli strains, contributing to a better understanding of the occurrence and pathogenic potential of these organisms.

The authors have declared no competing interest.

This study was funded by Oswaldo Cruz Institute grant, Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Processo SEI-260003/019688/2022.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Oswaldo Cruz Foundation Ethics Committee (CAAE:39978114.5.0000.5248).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript